Investigational COVID-19 Convalescent Plasma: Guidance for Industry | NLM

Disaster Information Management Research Center | NLM

Investigational COVID-19 Convalescent Plasma: Guidance for Industry

04/09/2020 12:00 AM EDT

Source: U.S. Food and Drug Administration (FDA). Published: 4/9/2020. This 12-page guidance provides recommendations to healthcare providers and investigators on the administration and study of investigational convalescent plasma collected from individuals who have recovered from COVID-19 (COVID-19 convalescent plasma) during the public health emergency. The guidance also provides recommendations to blood establishments on the collection of COVID-19 convalescent plasma. (PDF)